PEP-BPC-157-10-MG-TB-500 • RESEARCH USE ONLY

BPC-157 (10 mg) / TB-500

A synergistic nasal blend combining BPC-157 and TB-500, two powerful regenerative peptides that work together to accelerate tissue repair, reduce inflammation, and enhance recovery. This formulation supports soft-tissue healing, joint and connective-tissue repair, and systemic recovery from physical stress or injury.

10 mg / 10 mg

Per Bottle

— 62 mcg / 62 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use once or twice daily, depending on injury severity, inflammation levels, and recovery goals. For active injuries or high training load, twice-daily dosing may provide stronger results. This combination does not require fasted dosing: - May be taken with or without food - Many individuals tolerate it better with a small meal - Safe for extended use, though brief cycling helps maintain responsiveness.

Low

124 mcg BPC-157 + 124 mcg TB-500 (2 sprays)

Medium

250 mcg BPC-157 + 250 mcg TB-500 (4 sprays)

Higher

372 mcg BPC-157 + 372 mcg TB-500 (6 sprays)

Cycles

May be used continuously for 8–12 weeks
Take 1 week off every 8–12 weeks to maintain receptor sensitivity

Key Benefits

Promotes tissue repair and regeneration, reduces inflammation and pain, enhances healing response, improves recovery from training or injury, supports joint mobility, and strengthens connective tissue resilience.

Guidance

Start with 2 sprays once daily. 5 days on / 2 days off
Increase gradually only if needed
May split dosing morning / evening if using twice daily
Do not exceed 6 sprays per day unless directed
Ideal for injury recovery, inflammation reduction, and connective-tissue healing
Well tolerated and non-stimulatory
Pairs well with GHK-Cu or KPV for broader regenerative and anti-inflammatory support

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA